Chinook Therapeutics (NASDAQ:KDNY – Get Rating) released its quarterly results on Thursday. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.13, Fidelity Earnings reports. Chinook Therapeutics had a negative net margin of 199.39% and a negative return on equity of 26.45%.

Chinook Therapeutics stock traded down $0.86 at midday Friday, hitting $13.97. The stock had trading volume of 379,865 shares, compared to an average volume of 341,469. Chinook Therapeutics has a 52-week low of $10.48 and a 52-week high of $19.85. The company has a market capitalization of $767.67 million, a PE ratio of -5.82 and a beta of 0.10. The company’s fifty-day moving average is $14.82 and its two-hundred-day moving average is $14.51.

In other Chinook Therapeutics news, insider Andrew James King sold 5,000 shares of the company in a trade that took place on Monday, April 11. The stock was sold at an average price of $15.36, for a total value of $76,800.00. Following the completion of the transaction, the insider now directly owns 5,897 shares of the company, valued at approximately $90,577.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Company insiders own 23.38% of the company’s shares.

A number of hedge funds have been buying and selling KDNY shares recently. BlackRock Inc. increased its stake in Chinook Therapeutics by 17.8% in the fourth quarter. BlackRock Inc. now owns 2,987,931 shares of the company worth $48,733,000 after purchasing an additional 450,705 shares during the period. Affinity Asset Advisors LLC increased its position in Chinook Therapeutics shares by 52.2% during the first quarter. Affinity Asset Advisors LLC now owns 845,155 shares of the company valued at $13,827,000 after acquiring an additional 290,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Chinook Therapeutics shares by 78.3% during the first quarter. Dimensional Fund Advisors LP now owns 520,475 shares of the company valued at $8,515,000 after acquiring an additional 228,640 shares in the last quarter. Marshall Wace LLP purchased a new stock position in Chinook Therapeutics during Q4 valued at approximately $3,050,000. Finally, Geode Capital Management LLC increased its position in Chinook Therapeutics shares by 18.4% during the 4th quarter. Geode Capital Management LLC now owns 733,657 shares of the company valued at $11,965,000 after acquiring an additional 113,888 shares in the last quarter. Institutional investors and hedge funds own 84.23% of the company’s shares.

Separately, Zacks Investment Research downgraded shares of Chinook Therapeutics from a “buy” rating to a “hold” rating in a Tuesday, March 22 report.

About Chinook Therapeutics (Get a rating)

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, is focused on the discovery, development and commercialization of precision drugs for kidney disease. The Company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

Featured Articles

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Chinook Therapeutics right now?

Before you consider Chinook Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Chinook Therapeutics wasn’t on the list.

Although Chinook Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here